A double-blind trial of carbamazepine in negative symptom schizophrenia

T. Nachshoni*, Y. Levin, A. Levy, A. Kritz, M. Neumann

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Twenty-eight residual schizophrenics hospitalized in a chronic institution with a 9 to 30 year history of disease, with predominantly negative symptoms were given carbamazepine. Carbamazepine was administered in a double-blind trial and therapeutic effects were measured by the Scale for the Assessment of Negative Symptoms (SANS). Patients were also assessed for positive symptoms using the Brief Psychiatric Rating Scale (BPRS), for depression using the Hamilton Depression Scale, for extrapyramidal symptoms by the Simpson and Angus scale, to rule out these symptoms as sources of secondary negative symptoms. The study continued for 7 weeks with therapeutic carbamazepine levels achieved during the last 5 weeks. There was no significant positive effect of carbamazepine on negative symptoms.

Original languageEnglish
Pages (from-to)22-26
Number of pages5
JournalBiological Psychiatry
Issue number1
StatePublished - 1 Jan 1994
Externally publishedYes


  • Carbamazepine (therapeutic use)
  • negative symptom
  • schizophrenia


Dive into the research topics of 'A double-blind trial of carbamazepine in negative symptom schizophrenia'. Together they form a unique fingerprint.

Cite this